REMARKS

Upon entry of the foregoing amendment, claims 1, 3, 4, 6-8 and 11-19 are pending in this application. Claim 19 is newly added. Claims 2, 5, 9 and 10 have previously been canceled. Claims 4, 6-8 and 18 have been withdrawn from consideration as being directed to a non-elected invention. Claims 1, 3 and 19 are currently under examination.

Support for the amendments to claims 1, 15 and 16 (claims 15 and 16 are currently withdrawn) changing "mass" to "weight" are found, for example, on page 1, line 29; and, elsewhere throughout the specification. "kDa" is well known as an abbreviation for "kilodaltons," and is a measure of molecular weight. Therefore, it is believed that the change from "mass" to "weight" is also implicitly supported by the use of "kDa" in the specification.

New claim 19 finds support in claims 2-3 and elsewhere throughout the specification.

It is believed no new matter has been added has been introduced by this amendment and entry is respectfully requested.

Restriction

The Office has made the requirement for restriction FINAL. The restriction requirement is respectfully traversed.

In reply to the previous restriction requirement, Applicants elected Group I, claims 1-3, drawn to a peptide and asserted Groups II, III and IV should be joined and examined with the claims of

Group I in view of the presence of the single general inventive concept. However, the Office has maintained the restriction requirement, asserting the analysis of novelty is based on the claims as originally presented. The Office continues to assert the inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because under PCT Rule 13.2, the groups lack the same or corresponding special technical features.

Applicants assert that while each of the identified protein sequences has a different structure, the identified protein sequence SEQ ID NO: 5 is an embodiment of the genus of sequences included in claim 1. The elected species (SEQ ID NO: 6) is representative of the genus of the claim and the genus should be allowed or at least the additional species, representative of the genus, i.e., SEQ ID NO. 7, should be searched. The Office is reminded that if a generic claim is found to be allowable, the method claims should be rejoined and allowed as well. Therefore, the method claims, although currently withdrawn from examination, have been amended where necessary to conform to the 35 U.S.C. § 112, second paragraph, comments made by the Examiner regarding claims 1-3.

Objections to the specification

The Office has objected to the embedded hyperlinks. Accordingly, the specification has been amended to delete the link.

Use of Trademarks

The comments concerning the use of trademarks at page 3 of the Office Action are noted. Applicants do not believe the use of any term in the specification is improper.

Rejection of claims 1 and 3 under 35 U.S.C. § 112, second paragraph

Claims 1 and 3 have been rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The rejection is respectfully traversed.

The Office asserts the recitation of "molecular mass" is vague and indefinite. However, without acquiescing to the position of the Office, claim 1 (and withdrawn claims 15 and 16) have been amended to change the "mass" to "weight" as discussed above. In view of the amendments to the claims, the rejection is believed to be overcome. Reconsideration and withdrawal of the rejection is respectfully requested.

The Office also asserts the word "approximately" is vague and indefinite. However, contrary to the position of the Office, the word "approximately" is understood by one of ordinary skill in the art and is given its ordinary, common English language meaning. "Approximately" is defined in The American Heritage Dictionary (Second college Edition, Houghton Mifflin Company, New York and Boston, 1991, page 122) as "(3) Close together; near." or (2) "Very similar; closely resembling." Roget's Thesaurus (Roget's II, The New Thesaurus, 3rd edition, Houghton Mifflin Company, New York and Boston, 1995, page 47) defines "approximately" as meaning "Near to in quantity or amount: about, almost, nearly, roughly." Therefore, one of ordinary skill in the art would understand the meaning of the word "approximately." In addition, the meaning of the word "approximately" has been considered by the Federal Circuit. In *Quantum Corp. V. Rodime, Plc.*, 65 F. 3d. 1577, 36 USPQ2d 1162 (Fed. Cir. 1995), cert. denied, 517 U.S. 1167 (1996), the court determined the word "approximately" meant 'reasonably close to'. Thus, in the instant application, one of ordinary skill would interpret "approximately" as 'reasonably close to.' Applicants assert the word "approximately" is not vague and indefinite since one of ordinary skill would understand, for example, the phrase "a molecular weight of approximately 4.5 kDa" to refer to a molecular weight which is reasonably close to 4.5 kDa. Reconsideration and withdrawal of the rejection is respectfully requested.

Rejection of claims 1 and 3 under 35 U.S.C. § 102(a)

Claims 1 and 3 have been rejected under 35 U.S.C. § 102(a) as being anticipated by Mitta *et al.* (J. Cell. Science 113: 2759-279, 2000) and by Mitta *et al.* (Developmental and Comparative Immunology, 24;S1:S20, Meeting Abstract, July 3-6, 2000). Both rejections are respectfully traversed.

The Office asserts Applicants cannot rely upon the foreign priority papers to overcome either 102(a) rejection because a certified copy of the English language translation of FRANCE 99/08858 has not been made of record in accordance with 37 CFR § 1.55. In reply, submitted herewith is a certified copy of the English language translation of the priority document. This application is entitled to a priority date based on the filing date of the priority document (July 8, 1999). Therefore, both Mitta documents, having publication dates (2000) subsequent to the effective filing date of this application (1999), are not proper prior art. The submission of the certified copy of the English language translation of the priority document is believed to moot both rejections. Reconsideration and withdrawal of the rejections is respectfully requested.

Conclusion

The foregoing amendments and remarks are being made to place the application in condition for allowance. Applicants respectfully request reconsideration and the timely allowance of the pending claims. A favorable action is awaited. Should the Examiner find that an interview would be helpful to further prosecution of this application, the Examiner is invited to telephone the undersigned at his convenience.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of times fees, or credit any overpayment to Deposit Account 50-0310. This

paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Attachment:
Certified copy of the English language
translation of the priority document FRANCE 99/08858

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

By: Suzanne E. Ziska

Suzanne E. Ziska, Ph.D.
Reg. No. 43,371

Date: December 29, 2003
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Ave., N.W.
Washington, DC 20004
Customer No. 009629

IN THE MATTER OF American Patent in the names of CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, IFREMER filed under n° 10/030,231

I, Béatrice ORES,
36, rue de Saint-Pétersbour
75008 PARIS (FRANCE)

do solemnly and sincerely declare as follows:

1. that I am a qualified Patent Engineer and am well acquainted with both the French and English languages,

2. that the attached document is a true and correct translation of the specification n° 99 08858

   filed by CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, IFREMER, with their application for a Patent in France on July 8, 1999.

   for: "ANTIMICROBIAL PEPTIDES DERIVED FROM MOLLUSKS."

Declared by the said

Béatrice ORES

At Paris on December 22, 2003

ANTIMICROBIAL PEPTIDES DERIVED FROM MOLLUSCS

The invention relates to novel antimicrobial peptides produced by mollusks.

Polypeptides possessing antimicrobial properties are produced by a large variety of species (animal or plant species), in which they contribute to nonspecific mechanisms of defense against infections.

In the case of bivalve mollusks, to date, in *Mytilus galloprovincialis*, a peptide named MGD-1 has been identified, which is related to insect defensins [HUBERT et al., Eur. J. Biochem., 240, 302-306, (1996)]; peptides of the defensin family have also been demonstrated in *Mytilus edulis*, as have peptides named "mytilins" [CHARLET et al., J. Biol. Chem., 271, 21808-21813, (1996)].

The inventors have now demonstrated novel antimicrobial peptides produced by *Mytilus galloprovincialis*, which are different from the MGD1 defensins and form the previously known mytilins.

A subject of the present invention is antimicrobial peptides, hereinafter named: "myticins", which have the following characteristics:

- their molecular mass is approximately 4.5 kDa;
- their pI is approximately 8.7;
- they comprise 8 cysteine residues.

According to a preferred embodiment of an antimicrobial peptide in accordance with the invention, it comprises the following sequence (I) (1-letter code):

$$HX_1HX_2CTSYX_3CX_4KFCGTAX_5CTX_6YX_7CRX_8LHX_9GKX_{10}CX_{11}CX_{12}HCSR \quad (I)$$

in which: X_1 = P or S, X_2 = V or A, X_3 = Y or W, X_4 = S or G, X_5 = S or G, X_6 = R or H, X_7 = G or L, X_8 = N or V, X_9 = R or P, X_{10} = L or M, X_{11} = F or A, and X_{12} = L or H.

Advantageously, a peptide in accordance with the invention comprises one of the following sequences (Ia) or (Ib) (1-letter code):

HSHACTSYWCGKFCGTASCTHYLCRVLHPGKMCACVHCSR (Ia)
HPHVCTSYYCSKFCGTAGCTRYGCRNLHRGKLCFCLHCSR (Ib)

The sequences (Ia) and (Ib) represent the mature forms, isolated from the hemolymph of *Mytilus galloprovincialis*, of 2 myticins named Myticin a and Myticin b, the cDNAs of which have also been cloned by the inventors. By way of illustration of the subject of the present invention, the characteristics of Myticin a and Myticin b are more specifically indicated below.

The cDNA sequence and the polypeptide sequence of Myticin a are represented in the attached sequence listing, under the numbers SEQ ID NO: 1 and SEQ ID NO: 2. The cDNA sequence and the polypeptide sequence of Myticin b are represented in the attached sequence listing, under the numbers SEQ ID NO: 3 and SEQ ID NO: 4.

The 40 amino acid active peptide, corresponding to the sequence (I), and more particularly to one of the sequences (Ia) and (Ib), is flanked by a 20 amino acid signal sequence and by a 36 amino acid C-terminal peptide. The signal sequence is thought to enable the addressing of the translation product toward the endoplasmic reticulum. The C-terminal peptide would then enable addressing toward the cytoplasmic granules in which the myticins are stored in mature form, and/or protection of the cell against possible cytolytic activity of the mature peptide.

The molecular mass of the mature form of Myticin a is 4438 Da; the molecular mass of the mature form of Myticin b is 4562 Da.

Myticins exhibit no significant homology with the known antimicrobial peptides in the prior art, and define a novel group of antimicrobial peptides.

Myticins may be obtained by extraction from the mollusks which produce them, by peptide synthesis or, advantageously, by genetic engineering, expressing at least one nucleic acid sequence encoding a myticin, in a suitable host cell.

The present invention also encompasses nucleic acids comprising a sequence encoding a myticin, as defined above.

Nucleic acids in accordance with the invention may be obtained by screening nucleic acid libraries using oligonucleotides derived from the sequences SEQ ID NO: 1 or SEQ ID NO: 3, or from the sequences complementary thereto. The oligonucleotides which can be used for this purpose are also part of the subject of the present invention; advantageously, these oligonucleotides comprise at least 15 bp, and preferably at least 20 bp, of the coding region of one of the sequences SEQ ID NO: 1 or SEQ ID NO: 3, or of the sequence complementary thereto.

The nucleic acids in accordance with the invention also encompass the expression cassettes comprising at least one nucleic acid sequence encoding a myticin, placed under the transcriptional control of a suitable promoter.

The term "suitable promoter" is intended to mean any promoter which is functional in the host cell intended

to harbor the expression cassette. It may be a constitutive promoter or an inducible promoter; it may also be, when the cassette is intended for the expression of a myticin in an animal or a plant, a tissue-specific promoter.

An expression cassette in accordance with the invention may also comprise at least one sequence encoding a suitable addressing sequence; said addressing sequence may be chosen from those which are naturally associated with myticins, such as the signal sequences and/or the C-terminal sequences associated with the Myticin a and Myticin b isoforms described above; it is also possible to choose one or more heterologous addressing sequences which are functional in a given host cell: they may in particular be sequences which allow the addressing of a myticin toward a given cellular compartment, or its secretion into the culture medium.

A subject of the invention is also:

- recombinant vectors, characterized in that they comprise at least one nucleic acid sequence in accordance with the invention, encoding a myticin, and, in particular, vectors comprising an expression cassette as defined above.

- prokaryotic or eukaryotic cells transformed with at least one nucleic acid sequence in accordance with the invention. They may be cells in culture or cells which form part of an animal or plant multicellular organism. The nucleic acid sequence in accordance with the invention present in a transformed cell may be either incorporated into the chromosomal DNA of said cell, or be carried by an extrachromosomal vector.

A subject of the invention is also a method for producing a myticin, characterized in that it comprises

expressing said myticin in at least one transformed cell in accordance with the invention.

The myticins in accordance with the invention may be expressed in cultures of cells transformed using techniques similar to those used for antimicrobial peptides of the prior art, for example in insect cells, as described by HELLERS et al. [Eur. J. Biochem. 199, pp. 435-439, (1991)] for cecropins, or in yeast, as described by REICHHART et al. [Invertebrate Reproduction and Development, 21, pp. 15-24, (1992)].

They may also be expressed in transgenic animals or plants, in order to increase the resistance thereof to infections, as described, for example, by JAYNES et al. [Plant Science, 89, pp. 43-53 (1993)] in the case of peptides analogous to cecropin B, expressed in transgenic tobacco plants, or by NORELLI et al. [Euphytica, 77, pp. 123-128 (1994)] for transgenic apple tree plants expressing the attacin-E gene.

The myticins can be used in particular for producing anti-infectious, for example antibacterial or fungicidal, products, and in particular medicinal products.

Such products are applied for preventing and treating various microbial diseases, in very varied sectors, in particular in the domains of health and of agriculture, and in that of aquaculture, in order to limit the development of infectious diseases in breeding stocks.

The present invention will be more clearly understood from the further description which follows, which refers to examples of purification and of characterization of the myticins.

EXAMPLE 1: ISOLATION OF ANTIMICROBIAL PEPTIDES FROM THE HEMOLYMPH OF *MYTILUS GALLOPROVINCIALIS*

Preparation of the hemolymph fractions

An immune reaction is induced in adult mussels (*Mytilus galloprovincialis*) according to the following protocol: the liquid is removed from the shell, and 100 µl of a suspension of bacteria (10^9 bacteria/ml) or of fungi (suspension of hyphae at 1 OD at 600 nm), heat-killed beforehand, are injected into the adductor muscle. The hemolymph (approximately 0.5 ml/animal) is removed from the posterior adductor muscle using a syringe, in the presence of one volume of MAS (Modified Alsevier Solution) anti-aggregating buffer, and immediately centrifuged at 800g for 15 min at 4°C. Aprotinin (5 µg/ml) is added to the supernatant, corresponding to the plasmatic fraction, which is frozen (-80°C) until use, and the cell pellet is dried and stored at -80°C until use.

Purification of myticins

Plasmatic fraction: The plasma is diluted (1:1 v/v) in water sterilized by ultrafiltration (MilliQ), to which 0.1% of trifluoroacetic acid has been added. The pH is brought to 3.9 by adding 1 M HCl, with stirring, in an iced water bath for 30 min. After centrifugation (10 000 g, 20 min, 4°C), the supernatant is harvested and kept at 4°C until use.

Hemocytes: After thawing, the hemocyte pellet is resuspended in 5 volumes of 50 mM Tris buffer, pH 8.7, containing 50 mM NaCl, and homogenized. After centrifugation (10 000 g, 20 min, 4°C), the pellet containing the cellular organelles is taken up in 3 volumes of 2 M acetic acid and treated by sonication (3 × 30 s) in an iced water bath. After removal of the debris by

centrifugation (10 000 g, 20 min, 4°C), the acid extract is stored at 4°C until use.

HPLC purification

The plasmatic fraction or the acid extracts of hemocytes are loaded onto SEP-PAK C18 VAC columns (WATERS ASSOCIATES) pre-equilibrated with acidified (0.05% trifluoroacetic acid) water. After washing with the acidified water, 2 successive elutions are carried out with solutions of acetonitrile at 10% and 40% in acidified (0.05% trifluoroacetic acid) water. The fractions obtained are lyophilized and reconstituted with ultrafiltered water, before being subjected to reverse-phase HPLC chromatography.

All the HPLC purification steps were carried out on a BECKMAN GOLD HPLC system equipped with a BECKMAN 168 detector. The elution is monitored by measuring UV absorption at 225 nm.

Step 1: The fractions eluted on SEP-PAK at 40% of acetonitrile are loaded onto a SEPHASIL C18 reverse-phase HPLC column (250 mm × 4.1 mm) (PHARMACIA). Elution is carried out with a linear gradient of 5 to 50% of acetonitrile in the acidified water, for 90 min at a flow rate of 0.9 ml/min. The fractions corresponding to the absorbence peaks are collected in polypropylene tubes (MICROSORB, 75 × 12 mm, NUNC IMMUNOTUBES), dried under vacuum and reconstituted with ultrafiltered water, prior to testing their antimicrobial activity.

Step 2: The active fractions recovered at the end of step 1 are loaded onto a SEPHASIL C8 reverse-phase HPLC column (250 mm × 4.1 mm) (PHARMACIA). The elution is carried out, at a flow rate of 0.9 ml/min, with a linear gradient of 20 to 30% of acetonitrile in the acidified water for 40 min.

Step 3: The active fractions recovered at the end of step 2 are loaded onto a SEPHASIL C18 column (250 mm × 4.1 mm) (PHARMACIA), using the biphasic gradient described in step 2, at a flow rate of 0.9 ml/min.

Step 4: The final purification step is carried out on a DELTA PAK HPI C18 reverse-phase column (2 × 150 mm) (WATERS ASSOCIATES), using the biphasic gradient described in step 2, at a flow rate of 0.3 ml/min.

EXAMPLE 2: ANTIMICROBIAL ACTIVITY OF THE PEPTIDES OBTAINED

Microorganisms used:

The list of the microorganisms used to determine the antimicrobial activities of Myticin a and of Myticin b is indicated below, in table 1.

Antibacterial assays and determination of the MBC:

The minimum bactericidal concentration (MBC) of the peptides was determined according to the protocol described by HANCOCK et al. [http://www.interchg.ubc.ca/bobh/methods.htm].

A series of successive doubling dilutions of the peptides, in an aqueous solution containing 0.01% of acetic acid and 0.2% of bovine serum albumin (BSA), is prepared.

10 µl aliquots of each dilution are incubated in sterile 96-well polypropylene microtitration plates, in the presence of 100 µl of bacterial suspension at a starting optical density of A_{600} = 0.001, in MUELLER HINTON BROTH liquid medium. The incubation is carried out for 18 h at 37°C with stirring, except in the case of the marine bacteria, for which the incubation is carried out 25°C. The MBC is determined by plating out,

onto solid MUELLER HINTON AGAR medium, the content of the wells corresponding to the first 3 dilutions for which no bacterial growth is observed, and incubating at 37°C for 18 hours. The lowest concentration of peptide which prevents any residual formation of colonies corresponds to the MBC.

Antifungal activity:

The antifungal activity was determined by calculating the MIC (minimum inhibitory concentration) in a test of inhibition of *Fusarium oxysporum* growth in liquid phase, according to the protocol described by FELHBAUM et al. [J. Biol. Chem., 269: 33159-63, (1994)].

A series of successive doubling dilutions of the peptides is prepared as indicated above for determining the antibacterial activity.

80 µl of spores suspended (final concentration 10^4 spores/ml) in Potato Dextrose Broth medium (DIFCO) are added to 10 µl of peptide solution in sterile 96-well polypropylene microtitration plates. The final volume is adjusted to 100 µl by adding water. The growth inhibition is determined after incubation for 24 hours at 25°C in the dark, by observation under a microscope and measurement of the increase in the OD_{600}. The value of the MIC corresponds to a range (a-b) of peptide concentrations, in which (a) represents the highest concentration at which growth is observed, and (b) represents the lowest concentration which induces 100% growth inhibition.

Antiprotozoan activity:

The oyster-parasite protozoan *Perkinsus marinus* is cultured in DMEM medium (GIBCO), according to the protocol described by GAUTHIER and VASTA [J. Invertebr. Pathol., 66, 156-168, (1995)].

10 µM of purified peptide are added to 4×10^4 *P. marinus*, in seawater (final volume 20 µl). The mixture is incubated for 1 hour at room temperature. The viability of the parasites is estimated by staining with acridine orange and with ethidium bromide, as described by MORVAN et al. [J. Invertebr. Pathol., 69, 177-82 (1997)]. The maximum viability is evaluated, as a positive control, in samples to which the peptide has not been added.

The results of the various experiments carried out, for the Myticin a and Myticin b peptides, are illustrated by table 1 below; the biological activities are expressed in µM.

TABLE 1

	Myticin a	Myticin b
BACTERIA		
Gram-positive		
Micrococcus luteus	2.25-4.5	1-2
Bacillus megaterium	2.25-4.5	1-2
Staphylococcus aureus	>20	>20
Listeria monocytogenes	>20	>20
Aerococcus viridans	4.5-9	2-4
Enterococcus faecalis	>20	N.D.
Gram-negative		
Escherichia coli D31	>20	10-20
Salmonella newport	>20	>20
S. typhimurium	>20	>20
Brucella suis	>20	>20
Pseudomonas aeruginosa	>20	N.D.
Enteromonas aerogenes	>20	N.D.
Vibrio alginolyticus	>20	>20
V. vulnificus	>20	>20
V. splendidus	>20	>20

	Myticin a	Myticin b
FUNGI		
Fusarium oxysporum	>20	5-10
OYSTER-PARASITE PROTOZOAN		
Perkinsus marinus	>20	>20

N.D.: not determined

These results show that the 2 peptides are active, in particular on *Micrococcus luteus;* the Myticin b peptide also appears to be more active than the Myticin a peptide on *Micrococcus luteus, Escherichia coli* and *Fusarium oxysporum*.

EXAMPLE 3: MYTICIN PEPTIDE cDNA CLONING

A cDNA library was constructed in the ZAP EXPRESS vector (STRATAGENE) using total poly(A)$^+$ RNAs from adult mussel hemocytes. A DNA probe representing 83 bp of the Myticin a cDNA was constructed using the PCR SCRIPT Amp (SK+) cloning kit (STRATAGENE), and labeled by random priming using the READY-TO-GO DNA labeling kit (PHARMACIA), and used to screen the DNA library transferred onto HYBOND-N membranes (AMERSHAM). Hybridizations at high stringency were carried out overnight at 65°C in 5X Denhardt's solution, 5X SSPE, 0.1% SDS, 100 µg/ml of salmon sperm DNA. The filters, rinsed beforehand at 65°C in 0.5 X SSC solution containing 0.1% SDS, were autoradiographed. A secondary screening was carried out in order to purify the positive clones. The phagemids were obtained by *in vivo* excision and both of their strands were sequenced.

110 positive clones were obtained. Among these clones, 4 were sequenced, and correspond to the Myticin a and Myticin b peptides.

In both cases, the amino acid sequence deduced from the open reading frame begins with a 20 amino acid signal

peptide; this signal peptide is directly followed, at its C-terminal end, by a 40 amino acid peptide beginning with a histidine residue, which corresponds to the active form of the peptide; this active peptide is followed by a 36 amino acid C-terminal extension.

CLAIMS

1. An antimicrobial peptide, named myticin, characterized in that it can be obtained from a bivalve mollusk, and in that

- its molecular mass is approximately 4.5 kDa;
- its pI is approximately 8.7;
- it comprises 8 cysteine residues.

2. The peptide as claimed in claim 1, characterized in that it comprises the following sequence (I):

$$HX_1HX_2\underline{C}TSYX_3\underline{C}X_4KF\underline{C}GTAX_5\underline{C}TX_6YX_7\underline{C}RX_8LHX_9GKX_{10}\underline{C}X_{11}\underline{C}X_{12}H\underline{C}SR \quad (I)$$

in which: X_1 = P or S, X_2 = V or A, X_3 = Y or W, X_4 = S or G, X_5 = S or G, X_6 = R or H, X_7 = G or L, X_8 = N or V, X_9 = R or P, X_{10} = L or M, X_{11} = F or A, and X_{12} = L or H.

3. The peptide as claimed in claim 2, chosen from the group consisting of:

- a peptide comprising the following sequence (Ia):

HSHACTSYWCGKFCGTASCTHYLCRVLHPGKMCACVHCSR (Ia)

- a peptide comprising the following sequence (Ib):

HPHVCTSYYCSKFCGTAGCTRYGCRNLHRGKLCFCLHCSR (Ib).

4. A nucleic acid comprising a sequence encoding the peptide as claimed in any one of claims 1 to 3.

5. An oligonucleotide comprising a segment of at least 15 bp, and preferably at least 20 bp, of the nucleic acid as claimed in claim 4.

6. An expression cassette comprising at least one nucleic acid sequence as claimed in claim 4, under the transcriptional control of a suitable promoter.

7. A recombinant vector, characterized in that it comprises at least one nucleic acid sequence as claimed in claim 4.

8. A prokaryotic or eukaryotic cell transformed with a nucleic acid sequence as claimed in claim 4.

9. A method for producing the peptide as claimed in any one of claims 1 to 3, characterized in that it comprises expressing a nucleic acid as claimed in claim 4, in at least one transformed cell as claimed in claim 8.

10. The use of the peptide as claimed in any one of claims 1 to 3, for producing an antimicrobial agent.

SEQUENCE LISTING

<110> CNRS
IFREMER

<120> ANTIMICROBIAL PEPTIDES DERIVED FROM MOLLUSCS

<130> MJPcb644/43

<140>
<141>

<160> 4

<210> 1
<211> 663
<212> DNA
<213> Mytilus galloprovincialis

<220>
<221> CDS
<222> (43)..(330)

<220>
<221> mat_peptide
<222> (103)..(222)

<220>
<221> sig_peptide
<222> (43)..(102)

<400> 1
aaggataata ttttgattta actgcaaact caaacgtaca at atg aag gca aca 54
Met Lys Ala Thr
-20

atc ttg tta gca gtt cta gtg gca gtc ttt gtc gca ggt acg gaa gct 102
Ile Leu Leu Ala Val Leu Val Ala Val Phe Val Ala Gly Thr Glu Ala
-15 -10 -5 -1

cat tcg cac gct tgt aca tca tac tgg tgt ggt aag ttt tgt gga act 150
His Ser His Ala Cys Thr Ser Tyr Trp Cys Gly Lys Phe Cys Gly Thr
1 5 10 15

gct agt tgc aca cat tat cta tgc aga gta ctc cat ccc ggt aaa atg 198
Ala Ser Cys Thr His Tyr Leu Cys Arg Val Leu His Pro Gly Lys Met
20 25 30

tgc gca tgt gtt cat tgc agc agg gtg aac aat cct ttc aga gtt aat 246
Cys Ala Cys Val His Cys Ser Arg Val Asn Asn Pro Phe Arg Val Asn
35 40 45

caa gtt gct aaa agt att aac gat ttg gat tac act cca ata atg aag 294
Gln Val Ala Lys Ser Ile Asn Asp Leu Asp Tyr Thr Pro Ile Met Lys
50 55 60

tcg atg gaa aac ttg gac aat gga atg gat atg tta taagcaaaca 340
Ser Met Glu Asn Leu Asp Asn Gly Met Asp Met Leu
65 70 75

acttatgcaa tgcagatcac aactgtgaat ctttgctatc attctcactg cttttcacct 400

ttcaacaaac gaaaaattat cagcaacttg aaaaataaca aacttgagtc atgtctgttc 460

agtttccagt ctaatattta tatcattata tgaaaggtat aacaaaatta gtaccattgt 520

gttctaatag aaacaattta taaacaagaa acattacact ttaagtataa attaacagga 580

ttttgtcctg cagctgtttt atctttcttt tctcagctat agtcttctga ttgtaataaa 640

atagcttgaa aaaaaaaaaa aaa 663

<210> 2
<211> 96
<212> PRT
<213> Mytilus galloprovincialis

<400> 2

Met	Lys	Ala	Thr	Ile	Leu	Leu	Ala	Val	Leu	Val	Ala	Val	Phe	Val	Ala
1				5				10						15	
Gly	Thr	Glu	Ala	His	Ser	His	Ala	Cys	Thr	Ser	Tyr	Trp	Cys	Gly	Lys
			20					25					30		
Phe	Cys	Gly	Thr	Ala	Ser	Cys	Thr	His	Tyr	Leu	Cys	Arg	Val	Leu	His
		35					40					45			
Pro	Gly	Lys	Met	Cys	Ala	Cys	Val	His	Cys	Ser	Arg	Val	Asn	Asn	Pro
	50					55					60				
Phe	Arg	Val	Asn	Gln	Val	Ala	Lys	Ser	Ile	Asn	Asp	Leu	Asp	Tyr	Thr
65					70					75					80
Pro	Ile	Met	Lys	Ser	Met	Glu	Asn	Leu	Asp	Asn	Gly	Met	Asp	Met	Leu
				85					90					95	

<210> 3
<211> 681
<212> DNA
<213> Mytilus galloprovincialis

<220>
<221> CDS
<222> (13)..(300)

<220>
<221> mat_peptide
<222> (73)..(192)

<220>
<221> sig_peptide
<222> (13)..(72)

<400> 3

caaacgtaca	ac	atg	aag	gca	aca	atg	ttg	tta	gca	gtt	gta	gtg	gct	gtc	51
		Met	Lys	Ala	Thr	Met	Leu	Leu	Ala	Val	Val	Val	Ala	Val	
		-20					-15					-10			

ttt gtc gca ggt aca gaa gct cat ccg cat gtt tgc aca tcg tac tac 99

```
Phe Val Ala Gly Thr Glu Ala His Pro His Val Cys Thr Ser Tyr Tyr
       -5             -1   1              5

tgt agc aag ttt tgt ggg act gct ggt tgc aca cgt tat gga tgc cga   147
Cys Ser Lys Phe Cys Gly Thr Ala Gly Cys Thr Arg Tyr Gly Cys Arg
 10                  15                  20                  25

aat ctc cat cgc ggg aag ctt tgc ttc tgt ctt cat tgc agc agg gtg   195
Asn Leu His Arg Gly Lys Leu Cys Phe Cys Leu His Cys Ser Arg Val
                 30                  35                  40

aag ttc ccg ttt gga gca act caa gat gct aaa agt atg aac gaa ctg   243
Lys Phe Pro Phe Gly Ala Thr Gln Asp Ala Lys Ser Met Asn Glu Leu
             45                  50                  55

gaa tac act cca ata atg aag tcg atg gaa aat ttg gac aac gga atg   291
Glu Tyr Thr Pro Ile Met Lys Ser Met Glu Asn Leu Asp Asn Gly Met
         60                  65                  70

gat atg tta taagcaaact tatgacatga agatcacaac tgtatacttt           340
Asp Met Leu
     75

tgctattcct gtatccgctt tactcctttc ttcacacttt gtacggaatc cgtcaacaga 400

aaattcatca tcaacttgaa aactaacaaa agatgtgtcg cacacgttac actcaccagt 460

ccataagtta tatcattaaa aaaagatgaa tcaagttacc gttaacgtgt gttcagatat 520

atctctgaca gaagaagtaa ctgttaacaa gaaatactgt tttccctcaa gttattaaaa 580

attagaagtc tccctgcaac tgttttatct ttccttactc agttcttttt tcatgttcta 640

ataaaacagt ttgaaatgaa caaaaaaaaa aaaaaaaaaa a                     681


<210> 4
<211> 96
<212> PRT
<213> Mytilus galloprovincialis

<400> 4
Met Lys Ala Thr Met Leu Leu Ala Val Val Val Ala Val Phe Val Ala
  1               5                  10                  15

Gly Thr Glu Ala His Pro His Val Cys Thr Ser Tyr Tyr Cys Ser Lys
             20                  25                  30

Phe Cys Gly Thr Ala Gly Cys Thr Arg Tyr Gly Cys Arg Asn Leu His
         35                  40                  45

Arg Gly Lys Leu Cys Phe Cys Leu His Cys Ser Arg Val Lys Phe Pro
     50                  55                  60

Phe Gly Ala Thr Gln Asp Ala Lys Ser Met Asn Glu Leu Glu Tyr Thr
 65                  70                  75                  80

Pro Ile Met Lys Ser Met Glu Asn Leu Asp Asn Gly Met Asp Met Leu
                 85                  90                  95
```